

NCT00094861 Raw comparison:

Summary:
CHIA has 33 criteria while your personal folder has 34 criteria
Total found criteria: 33/33
Total not Found: 0/33
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Patients with a histologically or cytologically    │ Patients with a histologically or cytologically    │
│ proven diagnosis of NSCLC                          │ proven diagnosis of NSCLC                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unresectable (locally advanced) stage IIIa or IIIb │ Unresectable (locally advanced) stage IIIa or IIIb │
│ disease                                            │ disease                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Initial radiotherapy field of treatment to         │ Initial radiotherapy field of treatment to         │
│ encompass greater than or equal to 30% of the      │ encompass greater than or equal to 30% of the      │
│ esophagus                                          │ esophagus                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Life expectancy greater than or equal to 6 months  │ Life expectancy greater than or equal to 6 months  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Estimated weight loss less than or equal to 10% in │ Estimated weight loss less than or equal to 10% in │
│ the 3 months before study randomization            │ the 3 months before study randomization            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Measurable disease                                 │ Measurable disease                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ 18 years of age or older                           │ 18 years of age or older                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Eastern Cooperative Oncology Group (ECOG)          │ Eastern Cooperative Oncology Group (ECOG)          │
│ performance status of 0 - 2                        │ performance status of 0 - 2                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemoglobin (hgb) greater than or equal to 10 g/dL  │ Hemoglobin (hgb) greater than or equal to 10 g/dL  │
│ without transfusional support or growth factor use │ without transfusional support or growth factor use │
│ in the 4 weeks before study randomization          │ in the 4 weeks before study randomization          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Absolute neutrophil count (ANC) greater than or    │ Absolute neutrophil count (ANC) greater than or    │
│ equal to 1 5 x 10^9/L without growth factor use in │ equal to 1 5 x 10\^9/L without growth factor use   │
│ the 2 weeks before study randomization             │ in the 2 weeks before study randomization          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Platelet count greater than or equal to 100 x      │ Platelet count greater than or equal to 100 x      │
│ 10^9/L                                             │ 10\^9/L                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum bilirubin less than or equal to 1 5 x        │ Serum bilirubin less than or equal to 1 5 x        │
│ institutional upper limit of normal (ULN)          │ institutional upper limit of normal (ULN)          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum creatinine less than or equal to 2 0 mg/dL   │ Serum creatinine less than or equal to 2 0 mg/dL   │
│ (Note Patients with a serum creatinine greater     │ (Note Patients with a serum creatinine greater     │
│ than or equal to 1 4 and less than or equal to 2 0 │ than or equal to 1 4 and less than or equal to 2 0 │
│ mg/dL must demonstrate a 24-hour urinary           │ mg/dL must demonstrate a 24-hour urinary           │
│ creatinine clearance greater than or equal to 50   │ creatinine clearance greater than or equal to 50   │
│ mL/min)                                            │ mL/min)                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females of childbearing potential negative serum   │ Females of childbearing potential negative serum   │
│ or urine pregnancy test                            │ or urine pregnancy test                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient must give written informed consent before  │ Patient must give written informed consent before  │
│ participating in any study-specific procedure      │ participating in any study-specific procedure      │
│ randomization or receiving investigational product │ randomization or receiving investigational product │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with reproductive capability must agree   │ Patients with reproductive capability must agree   │
│ to practice adequate contraception methods         │ to practice adequate contraception methods         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Metastatic disease (M1)/stage 4 NSCLC              │ Metastatic disease (M1)/stage 4 NSCLC              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pleural or pericardial effusion greater than 100   │ Pleural or pericardial effusion greater than 100   │
│ ml in volume as documented by appropriate imaging  │ ml in volume as documented by appropriate imaging  │
│ (positron emission tomography [PET] computed       │ (positron emission tomography \[PET\] computed     │
│ tomography [CT] scan or ultrasound) If an effusion │ tomography \[CT\] scan or ultrasound) If an        │
│ greater than 100 ml is documented by cytology to   │ effusion greater than 100 ml is documented by      │
│ be free from malignancy and the investigator feels │ cytology to be free from malignancy and the        │
│ the patient is capable of receiving                │ investigator feels the patient is capable of       │
│ chemo/radiotherapy for their primary disease/      │ receiving chemo/radiotherapy for their primary     │
│ NSCLC the investigator should discuss the patient  │ disease/ NSCLC the investigator should discuss the │
│ with the study physician at Amgen Effusions        │ patient with the study physician at Amgen          │
│ smaller than 100 ml would be acceptable unless the │ Effusions smaller than 100 ml would be acceptable  │
│ investigator suspects that the effusion is         │ unless the investigator suspects that the effusion │
│ malignant in which case the effusions should be    │ is malignant in which case the effusions should be │
│ evaluated by cytology Sponsor approval must be     │ evaluated by cytology Sponsor approval must be     │
│ obtained before patient is randomized              │ obtained before patient is randomized              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Plan to remove the tumor surgically before         │ Plan to remove the tumor surgically before         │
│ completing the protocol chemo/radiotherapy course  │ completing the protocol chemo/radiotherapy course  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Shielding of any part of the esophagus during      │ Shielding of any part of the esophagus during      │
│ radiotherapy (including posterior spinal cord      │ radiotherapy (including posterior spinal cord      │
│ shielding)                                         │ shielding)                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior chemotherapy radiotherapy or surgery for     │ Prior chemotherapy radiotherapy or surgery for     │
│ NSCLC                                              │ NSCLC                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior invasive malignancy during the past 3 years  │ Prior invasive malignancy during the past 3 years  │
│ other than non-melanomatous skin cancer Note       │ other than non-melanomatous skin cancer Note       │
│ Patients with prior surgically-cured malignancies  │ Patients with prior surgically-cured malignancies  │
│ [eg stage I breast cancer or prostate cancer in-   │ \[eg stage I breast cancer or prostate cancer in-  │
│ situ carcinoma of the cervix etc] are not excluded │ situ carcinoma of the cervix etc\] are not         │
│ however sponsor approval must be obtained before   │ excluded however sponsor approval must be obtained │
│ patient is randomized                              │ before patient is randomized                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence or history of dysphagia or conditions     │ Presence or history of dysphagia or conditions     │
│ predisposing to dysphagia (eg uncontrolled         │ predisposing to dysphagia (eg uncontrolled         │
│ gastroesophageal reflux disease [GERD] dyspepsia   │ gastroesophageal reflux disease \[GERD\] dyspepsia │
│ etc)                                               │ etc)                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of pancreatitis                            │ History of pancreatitis                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Four weeks or less since completion of treatment   │ Four weeks or less since completion of treatment   │
│ using an investigational product/device in another │ using an investigational product/device in another │
│ clinical study or presence of any unresolved       │ clinical study or presence of any unresolved       │
│ toxicity from previous treatment                   │ toxicity from previous treatment                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous treatment on this study or with a         │ Previous treatment on this study or with a         │
│ fibroblast growth factor                           │ fibroblast growth factor                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known to be sero-positive for human                │ Known to be sero-positive for human                │
│ immunodeficiency virus (HIV) hepatitis C virus     │ immunodeficiency virus (HIV) hepatitis C virus     │
│ (HCV) or hepatitis B virus (HBV)                   │ (HCV) or hepatitis B virus (HBV)                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or breastfeeding women                    │ Pregnant or breastfeeding women                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known sensitivity to E coli derived products       │ Known sensitivity to E coli derived products       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Compromised ability of the patient to give written │ Compromised ability of the patient to give written │
│ informed consent and/or to comply with study       │ informed consent and/or to comply with study       │
│ procedures                                         │ procedures                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Refusal to sign an informed consent form to        │ Refusal to sign an informed consent form to        │
│ participate in this study and sign the hospital    │ participate in this study and sign the hospital    │
│ information release form if applicable             │ information release form if applicable             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unwilling or unable to complete the patient        │ Unwilling or unable to complete the patient        │
│ reported outcome (PRO) questionnaires              │ reported outcome (PRO) questionnaires              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Psychological social familial or geographical      │ Psychological social familial or geographical      │
│ reasons that would prevent regular follow-up       │ reasons that would prevent regular follow-up       │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛